Elizabeth P Henske
Tuberous sclerosis researcher and co-author of the 2026 TSC2 minipig study and the 2017 Cancer Cell paper on mTORC1 and nucleotide synthesis.
Brigham and Women's Hospital, Boston
Portrait: Mass General Brigham
Elizabeth P Henske is a co-author of two studies in the Atlas. In BOU2026 she is listed in the Division of Pulmonary and Critical Care Medicine at Brigham and Women's Hospital, where the team built a TSC2-mutant minipig that develops cardiac rhabdomyomas with active mTORC1 and an MITF/TFE lysosomal signature.
She also appears on VAL2017 in Cancer Cell, which showed that hyperactive mTORC1 couples nucleotide synthesis to demand, so that an imbalance leaves the cells vulnerable to replication stress.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2017 | M | mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability VAL2017 Co-author. Hyperactive mTORC1 ties nucleotide synthesis to demand, creating a targetable vulnerability. |
| 2026 | A | TSC2-Mutant Yucatan Minipig Cardiac Rhabdomyoma Model Reveals mTORC1 Activation and MITF/TFE Expression Signature BOU2026 Co-author. TSC2-mutant minipig model of cardiac rhabdomyoma with mTORC1 activation. |
Co-authors in the Atlas 6
People with a profile here who share at least one study with Elizabeth P Henske.
ShowHide
- David J. Kwiatkowski 2 shared studies Geneticist and physician who studies tuberous sclerosis complex (TSC) and the TSC1/TSC2 genes that restrain mTORC1.
- Alexander J. Valvezan Showed as a Manning-lab postdoc that mTORC1 matches nucleotide production to demand, creating a weak point that can be targeted in tumours with TSC loss. His Rutgers lab found that mTORC1 activity rises and falls through the cell cycle and helps drive entry into mitosis
- Brendan D. Manning Was among the groups that in 2002 identified TSC2 as a direct target of Akt (MAN2002), linking insulin and PI3K signalling to mTORC1, and later found TBC1D7 as the third subunit of the TSC complex. His lab has shown how mTORC1 turns growth signals into the synthesis of lipids and nucleotides
- Elias Bou Farhat First author of the 2026 JCI Insight paper on a TSC2-mutant minipig model of cardiac rhabdomyoma.
- John M. Asara Mass-spectrometry specialist whose core facility supplied metabolomics and proteomics for several mTOR studies, including measurements of purine, pyrimidine and SAM metabolism downstream of mTORC1.
- Marc Turner Research assistant and lab manager in Brendan Manning's mTOR lab at Harvard from 2014 to 2016, who contributed to studies on nucleotide synthesis in tumour cells and on metformin's route to mTORC1
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.